This review highlights recent progress in the management of chronic hepatitis B, C and D. New nucleoside and nucleotide analogs have recently been approved and are currently being evaluated for the treatment of chronic hepatitis B. At the same time, resistance is becoming an increasingly common clinical problem. Efforts are currently being made to individualize treatment regimens for patients with chronic hepatitis C, with the aim of enhancing efficacy and improving tolerability. Finally, recent studies using pegylated interferon-alpha have shown promising results for the treatment of chronic hepatitis D.